3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Withdrawn
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Leukemia, Myeloid, Acute
15
Precursor Cell Lymphoblastic Leukemia-Lymphoma
8
Leukemia, Lymphocytic, Chronic, B-Cell
7
Myelodysplastic Syndromes
6
Hematologic Neoplasms
6
Multiple Myeloma
5
Leukemia
5
Burkitt Lymphoma
5
Lymphoma, Non-Hodgkin
4
Lymphoma, Follicular
4
Lymphoma
4
Recurrence
3
Melanoma
3
Lymphoma, Mantle-Cell
3
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
3
Leukemia, Biphenotypic, Acute
3
Breast Neoplasms
3
Stomach Neoplasms
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Pancreatic Neoplasms
2
Neoplasms
2
Neoplasm Metastasis
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, B-Cell, Marginal Zone
2
Lymphoma, B-Cell
2
Leukemia, Prolymphocytic
2
Hematologic Diseases
2
Colorectal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma, Hepatocellular
2
Interventions
Paclitaxel
6
Radiotherapy
5
Carboplatin
5
capmatinib
2
Radiosurgery
2
Gemcitabine
2
tetrathiomolybdate
1
spartalizumab
1
pembrolizumab
1
palbociclib
1
onartuzumab
1
nintedanib
1
fludarabine phosphate
1
fludarabine
1
efaproxiral
1
durvalumab
1
binimetinib
1
aldesleukin
1
Vinorelbine
1
Technetium Tc 99m Sestamibi
1
Taxes
1
Sorafenib
1
Platinum
1
Nivolumab
1
Neoadjuvant Therapy
1
Magnetic Resonance Spectroscopy
1
Interleukin-2
1
Immunotherapy
1
Immunoenzyme Techniques
1
Gefitinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Adenocarcinoma of Lung
×
fludarabine
×
Clear all
NCT05566223
2026-02-23
CheckCell-2
Intima Bioscience, Inc.
Phase 1/2
Withdrawn